Zaleplon

CHEMBL1521 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

305.3 g/mol

LogP

1.0

Phase

4

This non-benzodiazepine sleep aid is prescribed for the short-term treatment of insomnia, specifically to help people fall asleep faster. It works by binding to GABA receptors in the brain in a way similar to benzodiazepines, producing a calming, sleep-inducing effect. Its very short duration of action means it is less likely to cause next-morning grogginess, but complex sleep behaviors (such as sleepwalking) have been reported.

Molekularmasse

305,3300 g/mol

LogP

1,00

TPSA

74,30 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Epilepsy Schizophrenia Generalized Anxiety Disorder Insomnia Obesity Hypertension Breast Cancer HIV/AIDS Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1

InChI

InChI=1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3

Molecular Formula

C17H15N5O

HBD / HBA

- / 4

Rotierbare Bindungen

3

Schwere Atome

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

This non-benzodiazepine sleep aid is prescribed for the short-term treatment of insomnia, specifically to help people fall asleep faster. It works by binding to GABA receptors in the brain in a way similar to benzodiazepines, producing a calming, sleep-inducing effect. Its very short duration of action means it is less likely to cause next-morning grogginess, but complex sleep behaviors (such as sleepwalking) have been reported.

Yes, Zaleplon is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1521. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5719. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Zaleplon auf PillFYI

Struktur

Schnelldaten

Formel: C17H15N5O
Synonyme: 1

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.